Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma
Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA filing acceptance and priority review for a New Drug Application (NDA) for vorasidenib, as well as the EMA granting…
SOUTH MUMBAI BASED 60+ YEAR OLD CMJ JAIN Hospital introduces IN A FIRST AS A CHARITABLE HOSPITAL, robotic surgery on SSI Mantra platform
CMJ Hospital, a beacon of healthcare for the poor & needy in Girgaon, Mumbai, with a legacy spanning 60+ years, has announced a groundbreaking advancement in surgical care with the introduction of robotic surgery on the SSI Mantra platform. This…
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Cell Stem Cell has published a paper titled “Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate.”…
New England Biolabs® Launches NEBNext® Enzymatic 5hmC-seq Kit, for enzyme-based 5hmC detection at single-base resolution
New England Biolabs (NEB®) today announced the launch of the NEBNext Enzymatic 5hmC-seq Kit (E5hmC-seq™), a novel enzyme-based method for the specific detection of 5hmC sites. The gentle, enzyme-based approach enables high yields and high-quality data, with an input range…
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced positive comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic candidate, from the Company’s recently…
MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology
MediLink Therapeutics (“MediLink”), announced today that it has entered into a worldwide collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors. Under…
The Inner Circle Acknowledges, Allan Lamb as a Pinnacle Platinum Healthcare Professional
Prominently featured in The Inner Circle, Allan Lamb is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the fields of General Surgery and Osteopathic Medicine. Dr. Lamb pursued higher education at Earlham College in 1989 where he earned a Bachelor of…
Ketamine Clinics Los Angeles (KCLA) Announces Free, Informative Webinar to Address Misconceptions Surrounding the Death of Actor Matthew Perry
Due to the media storm surrounding the recently announced cause of death for late actor Matthew Perry and his reported use of ketamine at the time of his death, leading mental health treatment center Ketamine Clinics Los Angeles (KCLA) announces a free, first-of-its-kind webinar…
NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it has signed a License Data and Technical Information Agreement with Columbia University for rights to data from a randomized, active-controlled trial of 80 patients hospitalized for…
Navamedic ASA: Renewed contract signed with Vitaflo International Limited
Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces it has renewed its contract with Vitaflo International Limited (Vitaflo International), granting Navamedic the exclusive rights to market and distribute Vitaflo…
